A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : PD-1

Search Conditions:
Search Keyword : PD-1
Search Method : Exact match.
Research Area:

Results:  
Hit abbr.: 2 kinds.
(Click one to see its hit entries.)

(Appearance freq, Descending)
Abbreviation: PD-1
Appearance Frequency: 3370 time(s)
Long forms: 38

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
programmed death-1
(3270 times)
Neoplasms
(1051 times)
PD-L1 (963 times)
CTLA-4 (386 times)
NSCLC (309 times)
0 [Advances in Immunotherapy of Malignant Melanoma].
programmed cell death 1 protein
(48 times)
Neoplasms
(14 times)
PD-L1 (17 times)
NSCLC (7 times)
OS (4 times)
2014 Ninety-day survival rate of patients with sepsis relates to programmed cell death 1 genetic polymorphism rs11568821.
programmed death-ligand 1
(8 times)
Neoplasms
(5 times)
NSCLC (4 times)
CTLA-4 (3 times)
AUC (2 times)
2015 An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
programmed death molecule-1
(4 times)
Medicine
(1 time)
CTLA-4 (2 times)
aGVHD (1 time)
CMV (1 time)
2009 Increased programmed death-1 molecule expression in cytomegalovirus disease and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
anti-PDCD1
(2 times)
Neoplasms
(1 time)
B2M (1 time)
FSP (1 time)
MMR (1 time)
2018 High numbers of PDCD1 (PD-1)-positive T cells and B2M mutations in microsatellite-unstable colorectal cancer.
anti-programmed cell death-1 protein receptor
(2 times)
Neoplasms
(2 times)
CI (1 time)
ctDNA (1 time)
ctDNA TMB (1 time)
2016 Biomarkers for PD-1/PD-L1 Blockade Therapy inNon-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
PD-L1/programmed cell death-1
(2 times)
Communicable Diseases
(1 time)
PD-L1 (2 times)
ADC (1 time)
APACHE (1 time)
2018 PD-L1 Overexpression During Endotoxin Tolerance Impairs the Adaptive Immune Response in Septic Patients via HIF1alpha.
PDCD1, CD279
(2 times)
Pathology
(1 time)
ALDH1 (1 time)
AML (1 time)
2018 Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.
Programmed death cell 1
(2 times)
Neoplasms
(1 time)
T1D (3 times)
CD (1 time)
PBMC (1 time)
2016 PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?
10  protein death-1
(2 times)
Immune System Diseases
(1 time)
CTLA-4 (1 time)
ICB (1 time)
2016 PD1-Expressing T Cell Subsets Modify the Rejection Risk in Renal Transplant Patients.
11  Anti(alpha)-programmed cell death-1
(1 time)
Immunotherapy
(1 time)
DLN (1 time)
IL (1 time)
M-MDSC (1 time)
2020 Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
12  anti-PD-1 was used to activate or block the programmed death
(1 time)
Medicine
(1 time)
CD28 (1 time)
ELISA (1 time)
IFN-gamma (1 time)
2019 PD-1/PD-L1 pathway activation restores the imbalance of Th1/Th2 and treg/Th17 cells subtypes in immune thrombocytopenic purpura patients.
13  anti-PD-L1/anti- programmed cell death 1
(1 time)
Neoplasms
(1 time)
DFS (1 time)
LNMs (1 time)
PD-L1 (1 time)
2018 Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
14  Anti-Programed Death 1
(1 time)
Neoplasms
(1 time)
AFP (1 time)
GCT (1 time)
2016 Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors.
15  CAMPANELLIProgrammed Death 1
(1 time)
Dental Pulp Diseases
(1 time)
PD-L1 (2 times)
2019 CAMPANELLIProgrammed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis.
16  death-protein 1
(1 time)
Drug Therapy
(1 time)
Ab (1 time)
CTL (1 time)
DCs (1 time)
2019 A Toll-like receptor 3 (TLR3) agonist ARNAX for therapeutic immunotherapy.
17  particularly antiprogrammed death 1
(1 time)
Neoplasms
(1 time)
CPI (1 time)
2019 Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
18  PD-1 decoy
(1 time)
Immunity
(1 time)
PD-L1 (1 time)
2016 Enhanced Anti-tumor Reactivity of Cytotoxic T Lymphocytes Expressing PD-1 Decoy.
19  PD-1 expressed on T cells and its ligands
(1 time)
Neoplasms
(1 time)
MDSC (1 time)
TAM (1 time)
TIL (1 time)
2013 Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.
20  PD-1 expression
(1 time)
Acquired Immunodeficiency Syndrome
(1 time)
ART (1 time)
2020 T cells with high PD-1 expression are associated with lower HIV-specific immune responses despite long-term antiretroviral therapy.
21  PD-1.1, PD-1.3, PD-1.5, PD-1.9
(1 time)
Clinical Medicine
(1 time)
CI (1 time)
CTLA-4 (1 time)
NSCLC (1 time)
2015 Polymorphisms of co-inhibitory molecules (CTLA-4/PD-1/PD-L1) and the risk of non-small cell lung cancer in a Chinese population.
22  PD-1ECD
(1 time)
Natural Science Disciplines
(1 time)
--- 2016 High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1.
23  PD-1ex
(1 time)
Hematology
(1 time)
AML (1 time)
BiTE (1 time)
CiTE (1 time)
2018 Bifunctional PD-1 alphaCD3 alphaCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.
24  PD-1hi
(1 time)
Allergy and Immunology
(1 time)
IO (1 time)
MIBC (1 time)
TME (1 time)
2018 Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment.
25  PD-L1 and its receptor
(1 time)
Hematology
(1 time)
PD-L1 (1 time)
2017 Clinical applications of PD-L1 bioassays for cancer immunotherapy.
26  PD-L1 mRNA levels were independent poor prognostic factors for OS
(1 time)
General Surgery
(1 time)
GC (1 time)
OS (1 time)
PB (1 time)
2018 Prognostic Impact of Immune-Related Gene Expression in Preoperative Peripheral Blood from Gastric Cancer Patients.
27  PDCD-1
(1 time)
Molecular Biology
(1 time)
ACT (1 time)
TIL (1 time)
ZFNs (1 time)
2015 Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma.
28  Pembrolizumab: a novel antiprogrammed death 1
(1 time)
Pharmacy
(1 time)
--- 2015 Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma.
29  percentages of GC TFH (CXCR5(high)PD-1(high)) and CXCR5(+)programmed cell death-1
(1 time)
Allergy and Immunology
(1 time)
EF (1 time)
GC (1 time)
Tfh (1 time)
2016 Germinal Center T Follicular Helper Cells Are Highly Permissive to HIV-1 and Alter Their Phenotype during Virus Replication.
30  pPD-1A
(1 time)
Biotechnology
(1 time)
GFP (1 time)
2004 [Eukaryotic expression and functional characterization of PD-1 extracellular domain].
31  Priya Darshini-1
(1 time)
Nutritional Sciences
(1 time)
PR (1 time)
1986 Genetic regulation of carotene biosynthesis in selected tomato strains: aspects of beta-carotene biosynthesis and B gene specificity.
32  Programmed Cell Death 1 ligand 1
(1 time)
Allergy and Immunology
(1 time)
--- 2015 Overcoming T cell exhaustion in infection and cancer.
33  programmed death 1 coinhibitory receptor
(1 time)
Biomedical Research
(1 time)
AML (1 time)
LAM (1 time)
TSC (1 time)
2018 TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy.
34  programmed death 1 on T cells
(1 time)
Neoplasms
(1 time)
AEs (1 time)
CTLA-4 (1 time)
HRQoL (1 time)
2017 Health-related quality of life results from the phase III CheckMate 067 study.
35  programmed death 1 pathway
(1 time)
Neoplasms
(1 time)
PD-L1 (1 time)
2015 Anti-PD-1 therapy in melanoma.
36  programmed death 1 positive
(1 time)
Medicine
(1 time)
BCL6 (1 time)
CD40L (1 time)
HC (1 time)
2016 [Detection of peripheral follicular helper T cells in rheumatoid arthritis].
37  Programmed death cell receptor 1
(1 time)
Allergy and Immunology
(1 time)
APC (1 time)
2011 Regulation of Trypanosoma cruzi-induced myocarditis by programmed death cell receptor 1.
38  programmed death-1 gene
(1 time)
Pediatrics
(1 time)
CAD (1 time)
KD (1 time)
OR (1 time)
2010 Programmed death-1 (PD-1) gene polymorphisms lodged in the genetic predispositions of Kawasaki Disease.